Viridian Therapeutics, Inc. (VRDN) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.99
↓-13% vs avg
5yr avg: 2.28
30Y Low0.5·High14.3
ROE
↑
-49.2%
↓+2% vs avg
5yr avg: -50.1%
30Y Low-251%·High-45%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VRDN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Viridian Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $2.6B | $1.3B | $975M | $937M | $236M | $59M | $15M | $90M | $201M | $54M |
| Enterprise Value | $1.3B | $2.5B | $1.2B | $893M | $787M | $194M | $13M | $-1500523 | $67M | $163M | $52M |
| P/E Ratio → | -5.11 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 20.32 | 37.25 | 4309.19 | 3104.38 | 528.93 | 79.53 | 55.73 | 3.37 | 10.70 | 50.14 | 16.25 |
| P/B Ratio | 1.99 | 3.65 | 1.94 | 2.21 | 2.37 | 1.26 | 0.49 | 0.95 | 1.75 | 5.21 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VRDN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 34.97 | 4049.26 | 2843.93 | 444.10 | 65.42 | 12.45 | -0.34 | 8.03 | 40.77 | 15.56 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
VRDN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Viridian Therapeutics, Inc. earns an operating margin of -512.9%. Operating margins have expanded from -81035.0% to -512.9% over the past 3 years, signaling improving operational efficiency. A negative ROE of -49.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2595.6% | 100.0% | -262.8% | -390.2% | 23.6% |
| Operating Margin | -512.9% | -512.9% | -99018.2% | -81035.0% | -7579.2% | -2690.8% | -10512.4% | -941.0% | -394.5% | -662.8% | -374.8% |
| Net Profit Margin | -483.6% | -483.6% | -89387.1% | -75711.5% | -7329.2% | -2680.2% | -10544.3% | -938.6% | -390.0% | -662.3% | -379.8% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.2% | -49.2% | -48.5% | -56.8% | -44.6% | -51.6% | -163.1% | -124.8% | -72.8% | -138.9% | -251.4% |
| ROA | -41.7% | -41.7% | -43.8% | -51.4% | -40.7% | -47.4% | -137.1% | -86.9% | -55.1% | -93.5% | -147.7% |
| ROIC | -47.3% | -47.3% | -47.0% | -63.1% | -51.6% | -54.2% | -224.3% | -222.9% | -165.3% | -2008.0% | — |
| ROCE | -47.7% | -47.7% | -51.6% | -58.8% | -45.4% | -51.3% | -156.9% | -105.6% | -61.3% | -110.0% | -247.5% |
VRDN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $212M exceeds total debt of $51M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.03 | 0.05 | 0.01 | 0.00 | 0.00 | 0.53 | 0.20 | 0.26 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.22 | -0.12 | -0.19 | -0.38 | -0.22 | -0.38 | -1.05 | -0.43 | -0.97 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -68.24 | -68.24 | -87.62 | -127.71 | -266.23 | -26470.00 | -79.76 | -49.15 | -36.46 | -68.22 | -132.41 |
Net cash position: cash ($212M) exceeds total debt ($51M)
VRDN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Viridian Therapeutics, Inc.'s current ratio of 12.65x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 18.26x to 12.65x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.65 | 12.65 | 15.43 | 18.26 | 12.73 | 14.68 | 12.14 | 2.92 | 9.71 | 13.31 | 0.93 |
| Quick Ratio | 12.65 | 12.65 | 15.43 | 18.26 | 12.93 | 14.68 | 12.14 | 2.92 | 9.71 | 13.31 | 0.91 |
| Cash Ratio | 12.37 | 12.37 | 14.99 | 17.92 | 12.73 | 14.44 | 11.96 | 2.64 | 9.28 | 12.17 | 0.73 |
| Asset Turnover | — | 0.08 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.15 | 0.13 | 0.08 | 0.78 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 39.81 |
| Days Sales Outstanding | — | — | — | 118.57 | 21.01 | 55.56 | — | 8.84 | 1.04 | 132.76 | 57.31 |
VRDN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Viridian Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% |
| Shares Outstanding | — | $85M | $68M | $45M | $32M | $12M | $4M | $2M | $2M | $1M | $721410 |
Peer Comparison
Compare VRDN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VRDNYou | $1B | -5.1 | — | — | 100.0% | -512.9% | -49.2% | -47.3% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 RDVT | $693M | 53.9 | 27.4 | 24.1 | 83.7% | 14.6% | 14.0% | 17.6% | 0.1 |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 AMGN | $178B | 23.1 | 14.1 | 21.9 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See VRDN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRDN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VRDN vs IMVT
Side-by-side business, growth, and profitability comparison vs Immunovant, Inc..
Start ComparisonVRDN — Frequently Asked Questions
Quick answers to the most common questions about buying VRDN stock.
What is Viridian Therapeutics, Inc.'s P/E ratio?
Viridian Therapeutics, Inc.'s current P/E ratio is -5.1x. This places it at the 50th percentile of its historical range.
What is Viridian Therapeutics, Inc.'s ROE?
Viridian Therapeutics, Inc.'s return on equity (ROE) is -49.2%. The historical average is -111.0%.
Is VRDN stock overvalued?
Based on historical data, Viridian Therapeutics, Inc. is trading at a P/E of -5.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Viridian Therapeutics, Inc.'s profit margins?
Viridian Therapeutics, Inc. has 100.0% gross margin and -512.9% operating margin.